Document Classification

Section Type: RESULTS

Text: At 24 months, the mitoxantrone group experienced benefits compared with the placebo group for the primary outcome (difference 0. 30 [95 % CI 0. 17-0. 44] ; p < 0. 0001) and the preplanned univariate analyses of those measures : change in expanded disability status scale (0. 24 [0. 04-0. 44] ; p = 0. 0194), change in ambulation index (0. 21 [0. 02-0. 40] ; p = 0. 0306), adjusted total number of treated relapses (0. 38 [0. 18-0. 59] ; p = 0. 0002), time to first treated relapse (0. 44 [0. 20-0. 69] ; p = 0. 0004), and change in standardised neurological status (0. 23 [0. 03-0. 43] ; p = 0. 0268).